Research investigating next-generation sequencing workflows for BRCA1/2 genes in samples associated with hereditary breast and ovarian cancer has shown outstanding performance, achieving nearly 100% sensitivity and specificity, while also proving to be cost-effective when compared to single-site mutation testing specifically for these genes (69). This evidence concerns the gene BRCA1 and ovarian cancer.